Get the Stockscreener App
251.22
0.71%
-1.7906
Alnylam Pharmaceuticals Inc stock is traded at $251.22, with a volume of 123.70K.
It is down -0.71% in the last 24 hours and down -8.29% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$253.01
Open:
$250.59
24h Volume:
123.70K
Relative Volume:
0.15
Market Cap:
$32.26B
Revenue:
$2.09B
Net Income/Loss:
$-332.26M
P/E Ratio:
-60.68
EPS:
-4.14
Net Cash Flow:
$16.06M
1W Performance:
-0.84%
1M Performance:
-8.29%
6M Performance:
+66.97%
1Y Performance:
+46.56%
1-Day Range:
$247.38
$253.21
1-Week Range:
$247.38
$256.02
52-Week Range:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
251.09 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.00 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.60 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
618.67 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
BNTX
Biontech Se Adr
|
117.50 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now? - Yahoo Finance
PDT Partners LLC Sells 10,800 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Bellevue Group AG Sells 110,739 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Eventide Asset Management LLC Has $61.70 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Cerity Partners LLC Increases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Suvretta Capital Management LLC Has $3.80 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
The Manufacturers Life Insurance Company Decreases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Antisense & RNAi Therapeutics Global Market Report 2024 To 2033 | - openPR
Alnylam Pharmaceuticals CEO sells $1.31 million in stock By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Penserra Capital Management LLC - MarketBeat
Alnylam Pharmaceuticals CMO Pushkal Garg sells $422,144 in stock - Investing.com India
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use - MSN
Alnylam Pharmaceuticals CSO sells $754,945 in stock By Investing.com - Investing.com Nigeria
Alnylam Pharmaceuticals CSO sells $754,945 in stock - Investing.com India
Alnylam Pharmaceuticals EVP Tanguler sells $368,685 in stock - Investing.com India
Alnylam Pharmaceuticals CEO sells $1.31 million in stock - Investing.com India
Alnylam Pharmaceuticals EVP Tanguler sells $368,685 in stock By Investing.com - Investing.com UK
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference - BioSpace
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Boosted by Algert Global LLC - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Swedbank AB - MarketBeat
Dyslipidemia Market Expected to Experience Major Growth - openPR
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis - MD Magazine
FDA Accepts Alnylam’s sNDA for Vutrisiran for ATTR-CM - MD Magazine
Gideon Hirshfield, FRCP, PhD: Developing Therapies to Address Pruritus in PBC - MD Magazine
Alnylam Pharmaceuticals (LTS:0HD2) Change In Working Capita - GuruFocus.com
ALNY (Alnylam Pharmaceuticals) EPS without NRI : $-1.21 (TTM As of Sep. 2024) - GuruFocus.com
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome - MD Magazine
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - BioSpace
US FDA approves BridgeBio's drug for rare heart condition (Nov 22) - Reuters
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Lowered by Loomis Sayles & Co. L P - MarketBeat
FDA reviews Alnylam's heart-related therapy application - Investing.com India
Alnylam's Vutrisiran FDA Review Set for ATTR-CM Treatment Expansion | ALNY Stock News - StockTitan
Charles Schwab Investment Management Inc. Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
What is Zacks Research's Estimate for ALNY FY2024 Earnings? - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Makes New $902,000 Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis - MSN
Principal Financial Group Inc. Reduces Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals announces interim Phase 1 data of nucresiran - MSN
FDA Approves Acoramidis (Attruby) for ATTR-CM - MD Magazine
BridgeBio heart drug approved by FDA, setting up battle with Pfizer - BioPharma Dive
John Tesser, MD: Improving Outcomes in RA With Vagus Nerve Stimulation - MD Magazine
RNAi Therapeutics Market Business Insights of Leading Players, - openPR
100,000 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Telemark Asset Management LLC - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Eagle Asset Management Inc. - MarketBeat
Alnylam Pharmaceuticals (STU:DUL) Cash Flow from Operations : €52 Mil (TTM As of Sep. 2024) - GuruFocus.com
(ALNY) Investment Report - Stock Traders Daily
Connor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Banque Cantonale Vaudoise Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Victory Capital Management Inc. Increases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Empowered Funds LLC Has $1.94 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Nov 26 '24 |
Sale |
250.98 |
1,682 |
422,144 |
17,457 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Nov 26 '24 |
Sale |
250.98 |
1,682 |
422,144 |
30,644 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Nov 26 '24 |
Sale |
250.98 |
1,469 |
368,686 |
13,191 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 27 '24 |
Sale |
252.29 |
1,531 |
386,261 |
12,881 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 26 '24 |
Sale |
250.98 |
1,469 |
368,686 |
14,412 |
0.10%
3.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):